Home › Pheochromocytoma › Maryland
Pheochromocytoma clinical trials in Maryland
10 studies for Pheochromocytoma are looking for participants at sites in Maryland.
Cities in Maryland
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Developmental Therapeutics ( Site 0108), Baltimore
- National Institutes of Health ( Site 0125), Bethesda
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Nov 13, 2026 · NCT04924075A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Nov 9, 2026 · NCT06041516Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 2 and older · All sexes · Updated Nov 4, 2026 · NCT0000123818F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 120 · All sexes · Updated Oct 29, 2026 · NCT06503146Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 100 · All sexes · Updated Oct 26, 2026 · NCT03206060Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Oct 16, 2026 · NCT06427798Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
- Johns Hopkins, Baltimore
RecruitingPhase 1/2
Ages 18 to 90 · All sexes · Updated Oct 13, 2026 · NCT05636618Diagnosis of Pheochromocytoma
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1
Ages 3 to 120 · All sexes · Updated Oct 8, 2026 · NCT00004847[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Oct 6, 2026 · NCT06479811Project: Every Child for Younger Patients With Cancer
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- and 1 more
RecruitingObservational study
Up to age 25 · All sexes · Updated Aug 25, 2026 · NCT02402244From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.